What we don’t cover: the longevity categories we leave out, and why

How we decide what to leave out

We review a category when two things are true. Public evidence lets you weigh a real benefit against cost, safety and trade-offs. And buying the product is a decision an adult can reasonably make without a prescriber.

A category stays off the site when at least one of four things is true. The product is really a medical treatment that should be decided with a clinician. Its main safety risk is serious and depends on supervision we can’t check. Its studies measure comfort or short-term recovery, not any outcome tied to healthy aging. Or its headline claims can’t be verified from public sources.

Leaving a category out isn’t a verdict on any product, clinic or prescriber. This page isn’t medical advice either. Some of these products may be pleasant or useful for reasons that have nothing to do with longevity. The table sums up where each category stands, and the sections below give the evidence and regulator sources behind each decision.

Soft-shell home hyperbaric chambers

Hyperbaric oxygen therapy means breathing oxygen inside a chamber pressurized above normal air pressure¹. The FDA regulates hyperbaric chambers as Class II medical devices, cleared through its 510(k) process¹. In medical practice, the Undersea and Hyperbaric Medical Society lists a defined set of uses³. They include decompression sickness, air or gas embolism, carbon monoxide poisoning, gas gangrene, selected problem wounds, delayed radiation injury, acute thermal burns and sudden sensorineural hearing loss³. The society defines the treatment as delivered at no less than 2.0 atmospheres absolute (ATA)³. It says scientifically supported treatments usually run between 1.9 and 3.0 ATA³.

Soft-shell home chambers are a different product. We read the FDA clearance for one flexible, portable fabric chamber². It covers treating mild symptoms consistent with acute mountain sickness, as prescribed by or under the direction of a physician². A compressor pressurizes the chamber with room air to less than 4 psi, and its relief valves are set at 4 psi². The hyperbaric society calls treatment below 1.5 ATA “mild hyperbaric oxygen” and says it’s unproven³. It also notes that clients of these treatments breathe gas mixes well below 95% oxygen³.

What the evidence shows: the main human study we found on hyperbaric oxygen and markers of aging didn’t use a soft chamber. The 2020 trial enrolled 35 healthy, independently living adults aged 64 and older⁴. The protocol called for 60 daily sessions over about three months⁴. Each session was 90 minutes of 100% oxygen at 2 ATA, in a multiplace chamber⁴. Telomere length in several types of blood immune cells rose by more than 20%, and senescent T-helper cells fell by about 37%⁴.

Certainty is low. There was no control group⁴. Of the 35 enrolled, 30 finished⁴. Only 25 were included in the telomere analysis⁴. Several authors declared employment with or shares in a private company⁴.

What it doesn’t show: none of this is evidence that a soft chamber slows aging, extends life or improves any health outcome in healthy adults. Soft chambers run at much lower pressure than the trial’s chamber, and the breathing gas is typically well below 95% oxygen³. Telomere length in blood cells is a lab marker, not a health outcome⁴.

Safety: on August 25, 2025, the FDA wrote to health care providers about hyperbaric oxygen therapy devices in general¹. It said it was aware of recent reports of fires with these devices that resulted in serious injuries and deaths¹. It added that the root cause wasn’t known¹. The FDA urged facilities to follow each device’s instructions for use and to account for the heightened fire risk of high-concentration oxygen. It also urged proper grounding, staff training, monitoring patients for the whole session and keeping out prohibited electrical or static-generating items¹.

The hyperbaric society adds that mild hyperbaric treatments aren’t physician-prescribed or supervised³. They’re often offered in wellness centers and spas³. The society says these facilities often operate without appropriate adherence to fire-safety and chamber-construction standards³.

Why we leave it out: the only soft-chamber use we found cleared is for short-term altitude sickness, under a physician’s direction. The recognized uses of hyperbaric oxygen are medical care, delivered at higher pressure by trained staff. That leaves no consumer buying decision we can responsibly rate.

GLP-1, peptide and hormone telehealth

Telehealth companies sell memberships that pair an online consultation with prescriptions for GLP-1 weight-loss drugs, peptides or hormones. Some market compounded versions rather than FDA-approved products^{7, 8}. Compounded drugs aren’t FDA-approved, and the FDA doesn’t review them for safety, effectiveness or quality before they’re sold^{5, 7}. This page doesn’t assess FDA-approved GLP-1 or hormone medicines.

Safety signals: as of May 31, 2026, the FDA had received 990 reports of adverse events associated with compounded semaglutide⁵. For compounded tirzepatide, it had received more than 730⁵. The FDA says these events are likely underreported, because state-licensed pharmacies that aren’t outsourcing facilities don’t have to report them to the agency⁵.

Some reports, including some that required hospitalization, may be tied to dosing errors⁵. The errors described include patients measuring and giving themselves the wrong dose and, in some cases, health care professionals miscalculating doses⁵. The FDA also says salt forms such as semaglutide sodium and semaglutide acetate are different active ingredients from those in approved drugs. It knows of no lawful basis for compounding with them⁵.

Enforcement: on February 6, 2026, the FDA said it intends to restrict GLP-1 active ingredients used in non-approved compounded drugs⁶. It said it can’t verify their quality, safety or efficacy, and it warned of possible seizure and injunction⁶. On March 3, 2026, it announced 30 warning letters to telehealth companies⁷. The letters targeted marketing that implied compounded products were the same as FDA-approved drugs, or that obscured who made them⁷.

In July 2025, the FTC took action against a telemedicine weight-loss firm that advertised memberships, typically at $138 or $188 a month⁸. It alleged the firm didn’t disclose that the price left out the GLP-1 drug itself, the required lab work and the prescribing consultation⁸. It also alleged the firm published fake testimonials and made unsubstantiated claims that members lose 53 pounds and 23% of their body weight on average⁸. Under a proposed settlement, the operators would pay $150,000, which the FTC expects to go toward consumer refunds⁸.

Peptides: the FDA keeps a page on bulk drug substances that may present significant safety risks in compounding⁹. The page, current as of April 22, 2026, lists BPC-157, TB-500 and CJC-1295 among substances whose nominations were withdrawn⁹. It says compounded BPC-157 may carry a risk of immune reactions for certain routes of administration⁹. It also cites possible peptide-related impurities and says the FDA has no, or only limited, safety information for the substance’s proposed routes of use⁹. For TB-500, the FDA identified no human exposure data⁹. For CJC-1295, it says it has identified serious adverse events, including increased heart rate⁹.

In July 2026, the FDA’s Pharmacy Compounding Advisory Committee was scheduled to discuss the list of substances pharmacies may compound with¹⁰. The question was whether to add BPC-157, TB-500, KPV, MOTs-C, emideltide, Semax and epitalon¹⁰. The meeting page we read reported no outcome¹⁰. The rules are moving, and a review written now could be out of date within months.

Hormones: in a 2020 analysis requested by the FDA, the National Academies of Sciences, Engineering, and Medicine looked at compounded bioidentical hormone therapy¹¹. It found a lack of rigorous evidence of safety and effectiveness¹¹. The information that did exist came mostly from low-quality data such as anecdotal claims, patient reports and prescriber testimonies¹¹. The National Academies concluded that the therapy’s widespread use poses a public health concern¹¹.

Why we leave it out: whether to start a prescription drug is a decision for a licensed clinician who knows your history. So are the dose and the monitoring that goes with it. Rating telehealth memberships on price and convenience would put a shopping frame around that medical decision, so we don’t.

Standalone mattress reviews

What the evidence shows: a 2021 systematic review covered 39 studies published through 2019¹². It concluded that a medium-firm mattress promotes comfort, sleep quality and spinal alignment¹².

Certainty is limited. Only seven of the 39 studies were randomized controlled trials¹². Another 27 were controlled trials without randomization¹². The individual studies the review describes ran for weeks to a few months, not years¹². The authors also noted contrasting results across studies, poorly standardized volunteers and poorly defined types of low back pain¹².

What it doesn’t show: the review reports outcomes for pain, stiffness, sleep quality, comfort and disability, but nothing on mortality or longevity¹². A mattress review here would come down to firmness, materials, price and return terms. That market is already crowded with brands and review sites, and we’d add little.

Claims: mattress marketing can also lean on chemical-free claims that are hard to verify, and regulators have challenged some of them. In 2013, the FTC announced proposed settlements with three mattress sellers¹³. The settlements barred the companies from claiming their mattresses were free of harmful volatile organic compounds (VOCs) without competent and reliable scientific evidence¹³. The FTC alleged that one company’s certification seal came from a certifier that was the company’s alter ego and that awarded the seal without objective standards¹³. Under the proposed orders, a VOC-free claim requires a VOC level of zero, or competent and reliable scientific evidence of no more than trace levels¹³.

Our sleep coverage sticks to products aimed at a specific factor, such as light or bed temperature, where you can compare specifications and running costs. Sheets and bed-climate systems stay in scope. Standalone mattresses don’t.

Vibration plates, massage guns and compression boots

These are sold mainly for recovery and relaxation. The research we found mostly measures short-term soreness, flexibility and muscle function, plus bone density for vibration plates^{14, 15, 17}.

Vibration plates: the clearest data are in postmenopausal women who already have osteoporosis. A 2024 meta-analysis included 13 randomized trials with 783 participants¹⁴. It found small average gains in bone mineral density at the lumbar spine (weighted mean difference 0.018; 95% CI 0.004 to 0.032)¹⁴. The femoral neck showed a small average gain too (0.005; 95% CI 0.001 to 0.011), but it only just reached statistical significance (P = 0.049)¹⁴. Pain scores were lower, and there was no significant effect on muscle or fat mass¹⁴. The abstract gives no rating of evidence certainty¹⁴.

Massage guns: a 2023 systematic review of 13 studies in adults found acute gains in strength, explosive strength and flexibility after a single session¹⁵. It also found less musculoskeletal pain with repeated sessions¹⁵. But every included study had limitations in methodological quality or reporting¹⁵.

A 2024 trial studied 17 untrained college-aged adults after 60 eccentric elbow contractions¹⁶. The nine who used percussive massage had about 6 to 8 degrees more range of motion than the eight controls¹⁶. They also got about one point of soreness relief on a 0 to 10 scale at each session¹⁶. The authors described the relief as immediate but temporary. They concluded that any effect on recovery from delayed-onset soreness didn’t appear until 72 hours after exercise¹⁶.

Compression boots: a 2024 meta-analysis included 17 studies with 319 athletic or healthy participants¹⁷. It found a trivial to small benefit for muscle function and a trivial to moderate effect on pain and soreness¹⁷. Effects on muscle-damage markers were highly variable¹⁷. Study quality ranged from fair to good on the PEDro scale¹⁷. The authors concluded only that the boots might help recovery, mainly by reducing perceived soreness¹⁷.

What it doesn’t show: the abstracts we read report no results for fractures, mortality or other long-term outcomes^{14, 15, 17}. The bone-density finding applies to postmenopausal women with osteoporosis, not to the typical healthy buyer¹⁴. The soreness findings come mostly from small, short studies of exercise recovery^15–17.

Why we leave them out: these are comfort and recovery products. Enjoying one is a fine reason to buy it. But rating them on a longevity site would imply a health benefit the evidence doesn’t show.

Deferred for now: non-toxic cookware and anti-aging skincare

Two categories are on hold rather than ruled out. Both rest on claims we can’t yet check from public sources to the standard we use elsewhere.

Non-toxic cookware: the FTC’s Green Guides say a non-toxic claim likely tells shoppers that a product is non-toxic for both people and the environment¹⁸. So marketers need competent and reliable scientific evidence for both, or must clearly and prominently qualify the claim¹⁸.

The underlying risks are real. Since August 2025, the FDA has warned about certain imported cookware made from aluminum, brass and aluminum alloys known as Hindalium or Indalium¹⁹. It says these may leach significant levels of lead into food¹⁹. Its list held 21 products as of December 2025¹⁹. The FDA notes there’s no known safe level of lead exposure¹⁹.

Checking a non-toxic claim for a specific pan means finding independent leach or composition testing for that exact product. We haven’t yet settled which tests we’d accept.

Anti-aging skincare: under federal law, a product applied to the body can be a cosmetic²⁰. But one intended to treat or prevent disease, or to affect the structure or any function of the body, can be a drug²⁰. The FDA gives claims to “regenerate cells” as an example that can make a product a drug²⁰. Cosmetics, apart from color additives, don’t need FDA approval before they go on sale, so a cream sold as a cosmetic can reach you without it²⁰.

We’ll revisit both once we have a clear, source-based method for judging their claims.

What would change our minds

We revisit this page when regulators act or major new evidence comes out. To come into scope, a category would need to clear the same bar as the rest of the site.

• Randomized trials or meta-analyses showing a meaningful longer-term outcome in the people who’d buy the product, not just short-term comfort or a lab marker
• Home hyperbaric chambers: a regulator clearance or safety standard covering unsupervised home use, for an outcome relevant to healthy adults
• Deferred categories: a published testing standard we can check product by product
• Prescription telehealth: our position is unlikely to change, because decisions about prescription drugs belong with a clinician

Sources

1. Follow Instructions for Safe Use of Hyperbaric Oxygen Therapy Devices: Letter to Health Care Providers US Food and Drug Administration, 2025 · regulator
2. 510(k) K101262: Flexi-Lite flexible hyperbaric chamber (clearance letter, indications for use and 510(k) summary) US Food and Drug Administration, 2010 · regulator
3. HBO Indications Undersea and Hyperbaric Medical Society, 2020 · guideline
4. Hyperbaric oxygen therapy increases telomere length and decreases immunosenescence in isolated blood cells: a prospective trial Aging (Albany NY), 2020
5. FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss US Food and Drug Administration, 2026 · regulator
6. FDA Intends to Take Action Against Non-FDA-Approved GLP-1 Drugs US Food and Drug Administration, 2026 · regulator
7. FDA Warns 30 Telehealth Companies Against Illegal Marketing of Compounded GLP-1s US Food and Drug Administration, 2026 · regulator
8. FTC Takes Action Against Telemedicine Firm NextMed Over Charges It Used Misleading Prices, Fake Reviews, and Deceptive Weight Loss Claims to Sell GLP-1 Weight-Loss Programs Federal Trade Commission, 2025 · regulator
9. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks US Food and Drug Administration, 2026 · regulator
10. July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee US Food and Drug Administration, 2026 · regulator
11. National Academies of Science, Engineering, and Medicine (NASEM) Study on the Clinical Utility of Treating Patients with Compounded "Bioidentical" Hormone Therapy US Food and Drug Administration · regulator
12. What type of mattress should be chosen to avoid back pain and improve sleep quality? Review of the literature Journal of Orthopaedics and Traumatology, 2021 · systematic review
13. Three Companies Barred from Advertising Mattresses as Free From Volatile Organic Compounds Without Scientific Evidence to Back Up Claims Federal Trade Commission, 2013 · regulator
14. Therapeutic effects of whole-body vibration on postmenopausal women with osteoporosis: a systematic review and meta-analysis Brazilian Journal of Medical and Biological Research, 2024 · meta-analysis
15. The Effect of Percussive Therapy on Musculoskeletal Performance and Experiences of Pain: A Systematic Literature Review International Journal of Sports Physical Therapy, 2023 · systematic review
16. Effects of Percussive Massage Treatments on Symptoms Associated with Eccentric Exercise-Induced Muscle Damage Journal of Sports Science and Medicine, 2024
17. Effects of lower-limb intermittent pneumatic compression on sports recovery: A systematic review and meta-analysis Biology of Sport, 2024 · meta-analysis
18. 16 CFR 260.10: Non-toxic claims (Guides for the Use of Environmental Marketing Claims) Federal Trade Commission, via the Electronic Code of Federal Regulations · regulator
19. FDA Issues Warning About Imported Cookware That May Leach Lead: August 2025 US Food and Drug Administration, 2025 · regulator
20. Is It a Cosmetic, a Drug, or Both? (Or Is It Soap?) US Food and Drug Administration, 2024 · regulator